首页 › 基金 › TWIN FOCUS CAPITAL PARTNERS, LLC › CGEM
TWIN FOCUS CAPITAL PARTNERS, LLC 对 CGEM 的持仓历史
CULLINAN THERAPEUTICS INC · 医疗保健
TWIN FOCUS CAPITAL PARTNERS, LLC 在 Q3 2026 的 13F 申报中披露持有 CGEM(CULLINAN THERAPEUTICS INC)595,489 股,市值约 US$9.1M,约占其申报组合的 0.85%,在其申报持仓中市值排名第 29 位。 TWIN FOCUS CAPITAL PARTNERS, LLC 最近 10 个申报季度中有 10 个季度披露了 CGEM 持仓,最早可追溯至 Q2 2024。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
TWIN FOCUS CAPITAL PARTNERS, LLC 对 CGEM 的持仓演变
TWIN FOCUS CAPITAL PARTNERS, LLC 于 Q2 2024 首次披露 CGEM 持仓:595,489 股(约 US$10.4M)。 该持仓在 Q2 2026 达到峰值 595,489 股,市值约 US$10.8M。 在 10 次申报中,TWIN FOCUS CAPITAL PARTNERS, LLC 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 595,489 股、市值约 US$9.1M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2024 | 595.49K | $10.39M | 新进 |
| Q3 2024 | 595.49K | $9.97M | 持有 |
| Q4 2024 | 595.49K | $7.25M | 持有 |
| Q1 2025 | 595.49K | $4.51M | 持有 |
| Q2 2025 | 595.49K | $4.48M | 持有 |
| Q3 2025 | 595.49K | $3.53M | 持有 |
| Q4 2025 | 595.49K | $6.16M | 持有 |
| Q1 2026 | 595.49K | $8.46M | 持有 |
| Q2 2026 | 595.49K | $10.84M | 持有 |
| Q3 2026 | 595.49K | $9.14M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CGEM 与 13F 数据
CGEM(CULLINAN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 33 只申报持有 CGEM,申报仓位最大的包括:MPM BioImpact LLC (US$177.2M), Lynx1 Capital Management LP (US$163.2M), BVF INC/IL (US$104.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CGEM 的基金
- MPM BioImpact LLC 9.73M 股 · $177.21M · Q2 2026
- Lynx1 Capital Management LP 8.96M 股 · $163.23M · Q2 2026
- BVF INC/IL 5.75M 股 · $104.72M · Q2 2026
- Kynam Capital Management, LP 3.11M 股 · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M 股 · $43.05M · Q2 2026
- Siren, L.L.C. 1.79M 股 · $27.53M · Q3 2026
- Venrock Adviser, LLC 1.38M 股 · $25.13M · Q2 2026
- Blue Owl Capital Holdings LP 1.40M 股 · $21.49M · Q3 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M 股 · $19.71M · Q2 2026
- Affinity Asset Advisors, LLC 875.76K 股 · $13.44M · Q3 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K 股 · $12.83M · Q2 2026
- Elmind Capital, LP 690.00K 股 · $12.56M · Q2 2026
更多关于 TWIN FOCUS CAPITAL PARTNERS, LLC
常见问题
How long has TWIN FOCUS CAPITAL PARTNERS, LLC held CGEM?
TWIN FOCUS CAPITAL PARTNERS, LLC has disclosed CGEM holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is TWIN FOCUS CAPITAL PARTNERS, LLC's current position in CGEM?
As of Q3 2026, TWIN FOCUS CAPITAL PARTNERS, LLC holds 595.49K shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $9.14M, representing 0.85% of its reported portfolio and ranking #29.
Has TWIN FOCUS CAPITAL PARTNERS, LLC been buying or selling CGEM?
In the latest 13F filing (Q3 2026), TWIN FOCUS CAPITAL PARTNERS, LLC held unchanged its position in CGEM. The position peaked in Q2 2026 at 595.49K shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.